Author

D. Gilham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

E. Kulikowski· 2 shared L. Fu· 2 shared M. Sweeney· 2 shared A. L. Smith· 1 shared A. Muralidharan· 1 shared A. Suhrbier· 1 shared B. Griffen· 1 shared B. W. C. Tse· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

E. Kulikowski

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-CoV-2 Infection in vitro

D. Gilham, A. L. Smith, L. Fu, D. Y. Moore, A. Muralidharan, S. P. M. Reid, S. C. Stotz, J. O. Johansson, M. Sweeney, N. C. Wong, E. Kulikowski, D. El-Gamal

This study shows apabetalone reduces ACE2 and DPP4 expression and inhibits SARS-CoV-2 infection in vitro, suggesting it could be a potential therapeutic for COVID-19.

bioRxiv · Mar 10, 2021Pharmacology & Toxicology

Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical)

R. J. Mills, S. J. Humphrey, P. R. Fortuna, M. Lor, S. R. Foster, G. A. Quaife-Ryan, R. L. Johnston, T. Dumenil, C. Bishop, R. Ruraraju, D. J. Rawle, T. Le, W. Zhao, L. Lee, C. Mackenzie-Kludas, , E

The paper identifies BET inhibitors as potential cardio-protective drugs that block inflammation-induced cardiac dysfunction and SARS-CoV-2 infection in pre-clinical models.

bioRxiv · Aug 23, 2020 · PreprintCell Biology